Urotronic announced that the FDA approved its Optilume BPH catheter system for to alleviate urinary symptoms caused by BPH.
Minneapolis-based Urotronic designed Optilume as a minimally invasive surgical therapy. It combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel. This treats lower urinary tract symptoms secondary to BPG (benign prostatic hyperplasia).
Urotronic previously received FDA approval Optilume for the treatment of male urethral strictures. In these cases, the balloon inhibits new scar tissue growth that can occur after endoscopic dilations.
Get the full story at our sister site, Medical Tubing & Extrusion.